Active substance amivantamab
Holder Janssen-Cilag
Status Running
Indication treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) who have epidermal growth factor receptor (EGFR) Exon 20 insertion (Exon20ins), and whose disease has progressed during or after current standard of care platinum-based chemotherapy.
Public documents Approbation
  Approbation - Amendment
  Information for the patient
  Information for the patient - amendment
  Informed Consent
  Informed Consent - amendment
Last update



Last updated on 27/11/2023